NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Sonoma Pharmaceuticals, Inc. (SNOA) Stock Analysis

Sonoma Pharmaceuticals, Inc. (SNOA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

SNOA

$1.33

+$0.01 (+0.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SNOA with… →

SNOA Key Statistics

As of Sep 4, 2026
Trading
Open
$1.30
Previous Close
$1.32
Day's Range
1.28–1.33
52-Week Range
0.85–4.70
Volume
92.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.31
Valuation
Market Cap
$6.34M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.08
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.29
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.22
Financials (FY)
Revenue (FY)
$19.53M+36.68%
Net Income (FY)
−$3.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
−10.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.79M
1-Year Return
−70.64%
Dividend and dates
Avg Volume
153.07K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SNOA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−63.46%
2025+35.32%
2024−25.28%
2023−83.93%
2022−75.44%
2021−37.19%
2020+66.51%
2019−31.77%
2018−86.97%
2017+8.13%
2016 (partial year)+32.28%

As of September 4, 2026.

SNOA Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$19.53M−$3.18M−16.3%
2024$14.29M−$3.46M−24.2%
2023$12.74M−$4.84M−38.0%
2022$13.27M−$5.15M−38.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$19.53M$7.42M−$2.46M−$3.18M−16.3%
2024$14.29M$5.47M−$3.71M−$3.46M−24.2%
2023$12.74M$4.75M−$4.70M−$4.84M−38.0%
2022$13.27M$4.48M−$4.57M−$5.15M−38.8%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

SNOA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricSNOADrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.292.300.1x the median
Profit margin−10.33%−3.14%7.2 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Sonoma Pharmaceuticals, Inc. (SNOA) is capitalised at $6.34M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 10 employees.

The 52-week range on file runs from $0.85 to $4.70. SNOA last closed at $1.33 on September 4, 2026. That is +$0.01 (+0.76%) against the previous close. The latest close sits 56.47% above that 52-week low.

Financial Health

In fiscal 2025, Sonoma Pharmaceuticals, Inc. reported revenue of $19.53M. Against the prior fiscal year total of $14.29M, that is a change of +36.68%. The same year closed with a net loss of $3.18M. Profit margin runs at −10.33%. That is 7.2 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −1.22.

Across the 4 fiscal years on file, revenue moves from $13.27M in 2022 to $19.53M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.08. The price-to-sales ratio is 0.29. On price-to-sales that is 0.1 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −70.64%. Across 10 years the annualized return works out at −46.89%. Beta against the wider market is reported at 1.31. Daily returns over the trailing 10 years annualize to a volatility of 104.66%.

Growth & Income

The record shows no dividend for SNOA.

So far in 2026 the price is −63.46%. Across the complete calendar years on file, 2020 returned +66.51% and 2018 returned −86.97%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Sonoma Pharmaceuticals, Inc. (SNOA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sonoma Pharmaceuticals, Inc. SNOA $6.34M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Sonoma Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Visit website →